0N6Z Stock Overview
Develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Biotest Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €43.00 |
| 52 Week High | €44.01 |
| 52 Week Low | €41.90 |
| Beta | 0.45 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | 55.87% |
| Change since IPO | 187.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0N6Z | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.1% | -1.5% |
| 1Y | n/a | -25.8% | 5.8% |
Return vs Industry: Insufficient data to determine how 0N6Z performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0N6Z performed against the UK Market.
Price Volatility
| 0N6Z volatility | |
|---|---|
| 0N6Z Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.8% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0N6Z has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0N6Z's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 1,967 | Michael Ramroth | www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas.
Biotest Aktiengesellschaft Fundamentals Summary
| 0N6Z fundamental statistics | |
|---|---|
| Market cap | €1.53b |
| Earnings (TTM) | -€54.20m |
| Revenue (TTM) | €511.50m |
2.7x
P/S Ratio-25.7x
P/E RatioIs 0N6Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0N6Z income statement (TTM) | |
|---|---|
| Revenue | €511.50m |
| Cost of Revenue | €427.60m |
| Gross Profit | €83.90m |
| Other Expenses | €138.10m |
| Earnings | -€54.20m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 11, 2022
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 16.40% |
| Net Profit Margin | -10.60% |
| Debt/Equity Ratio | 142.4% |
How did 0N6Z perform over the long term?
See historical performance and comparison